Liquid Lipids Act as Polymorphic Modifiers of Tristearin-Based Formulations Produced by Melting Technologies

Despite the growing interest in lipid-based formulations, their polymorphism is still a challenge in the pharmaceutical industry. Understanding and controlling the polymorphic behavior of lipids is a key element for achieving the quality and preventing stability issues. This study aims to evaluate t...

Full description

Saved in:
Bibliographic Details
Main Authors: Serena Bertoni (Author), Nadia Passerini (Author), Beatrice Albertini (Author)
Format: Book
Published: MDPI AG, 2021-07-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_b11a58bf26fe4156ab83c53dd3f1563d
042 |a dc 
100 1 0 |a Serena Bertoni  |e author 
700 1 0 |a Nadia Passerini  |e author 
700 1 0 |a Beatrice Albertini  |e author 
245 0 0 |a Liquid Lipids Act as Polymorphic Modifiers of Tristearin-Based Formulations Produced by Melting Technologies 
260 |b MDPI AG,   |c 2021-07-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics13071089 
500 |a 1999-4923 
520 |a Despite the growing interest in lipid-based formulations, their polymorphism is still a challenge in the pharmaceutical industry. Understanding and controlling the polymorphic behavior of lipids is a key element for achieving the quality and preventing stability issues. This study aims to evaluate the impact of different oral-approved liquid lipids (LL) on the polymorphism, phase transitions and structure of solid lipid-based formulations and explore their influence on drug release. The LL investigated were isopropyl myristate, ethyl oleate, oleic acid, medium chain trigycerides, vitamin E acetate, glyceryl monooleate, lecithin and sorbitane monooleate. Spray-congealing was selected as an example of a melting-based solvent-free manufacturing method to produce microparticles (MPs) of tristearin (Dynasan<sup>®</sup>118). During the production process, tristearin MPs crystallized in the metastable α-form. Stability studied evidenced a slow phase transition to the stable β-polymorph overtime, with the presence of the α-form still detected after 60 days of storage at 25 °C. The addition of 10% <i>w/w</i> of LL promoted the transition of tristearin from the α-form to the stable β-form with a kinetic varying from few minutes to days, depending on the specific LL. The combination of various techniques (DSC, X-ray diffraction analysis, Hot-stage polarized light microscopy, SEM) showed that the addition of LL significantly modified the crystal structure of tristearin-based formulations at different length scales. Both the polymorphic form and the LL addition had a strong influence on the release behavior of a model hydrophilic drug (caffeine). Overall, the addition of LL can be considered an interesting approach to control triglyceride crystallization in the β-form. From the industrial viewpoint, this approach might be advantageous as any polymorphic change will be complete before storage, hence enabling the production of stable lipid formulations. 
546 |a EN 
690 |a spray congealing 
690 |a lipid microparticles 
690 |a triacylglycerol 
690 |a drug release 
690 |a stability 
690 |a polymorphism 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 13, Iss 7, p 1089 (2021) 
787 0 |n https://www.mdpi.com/1999-4923/13/7/1089 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/b11a58bf26fe4156ab83c53dd3f1563d  |z Connect to this object online.